The Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The law generally requires a 30-day waiting period for a merger or acquisition to close so regulators have enough time to investigate the deal. Cardinal announced the deal last month, noting that adding Kinray would help expand its presence in the lucrative New York market.
Cardinal Health Inc. (NYSE:CAH) has renewed its agreement to supply pharmaceuticals to Walgreen Co.'s national network of retail pharmacies. The Walgreen deal is a critical one for Cardinal. Walgreen accounted for 24 percent of its revenues in each of the last two years -- more than any other customer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
With Cardinal Health Inc. (NYSE:CAH) buying a Chinese pharmaceuticals distributor, the Ohio company has become the first of the three major U.S. drug distributors to make a big investment outside North America. But it likely won't be the last time one of the Big Three look across the world's oceans in search of growth opportunities.
Cardinal Health Inc. (NYSE:CAH) has purchased a Chinese pharmaceuticals distributor, giving the Dublin, Ohio, company greater access to what's expected to become the world's second-largest drug distribution market.
Investors showed their approval of Cardinal Health Inc.'s (NYSE:CAH) $1.3 billion acquisition of drug distributor Kinray Inc., bidding up Cardinal's shares to their largest daily gain in a year and a half on Thursday.
The acquisition of Kinray Inc. for $1.3 billion will allow Cardinal to significantly expand its retail business with independent pharmacies and offers the Dublin, Ohio-based company access to the lucrative New York metropolitan area market.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Indianapolis drug maker Eli Lilly & Co. (NYSE:LLY) has agreed to pay up to $800 million for Avid Radiopharmaceuticals, the Philadelphia developer of a tracing agent that can help diagnose Alzheimer's disease. The tracing agent, florbetapir F 18 -- which last week topped the Cleveland Clinic's Top 10 Medical Innovations list for 2011 -- is coupled with a PET scan to allow doctors to see inside patients' brains to detect beta-amyloid plaques, the tell-tale signature of Alzheimer's.
It was all smiles, happy talk and back-slapping at Cardinal Health Inc.'s (NYSE:CAH) annual shareholders meeting Wednesday, the Columbus Dispatch reported. And why would shareholders be anything but happy? Cardinal is up 11.4 percent for the year. And Tyler Durden probably is the biggest reason why.
First quarter profits for medical products and pharmaceuticals supplier Cardinal Health Inc. (NYSE:CAH) beat analysts expectations, though sales slipped slightly.
Medical products supplier Cardinal Health Inc. (NYSE:CAH) took the unusual step Tuesday afternoon of publicly responding to rumors of an imminent sale to a private equity firm.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Mammotome, the new name for the former the breast-care business of Johnson & Johnson's Ethicon Endo-Surgery, has hired a number of senior executives as the company rounds out its leadership team.
Pharmaceutical and medical products supplier Cardinal Health Inc. has sold its remaining stake in spinoff medical technology company CareFusion for $706 million.
Cardinal Health Inc. (NYSE: CAH) continues to feel the love from credit ratings agencies, with Fitch upgrading the Ohio company's outlook to "positive." Fitch attributed the change in Cardinal Health's outlook to the company's focus on paying down debt, and expected strong financial performance and disciplined acquisition activity over the next year.
Cardinal Health Inc. (NYSE: CAH) will manage and operate the Knoxville, Tennessee, cyclotron facility of ProVision Healthcare through an agreement that expands the Dublin, Ohio, drug distributor's ability to make molecular imaging agents nationwide. Ohio's largest corporation has been partnering with academia and industry to push the boundaries of nuclear medicine -- and have first dibs on commercializing the industry's innovations -- by using its know-how and technologies to enable researchers to come up with new products.
Cardinal Health (NYSE: CAH) Foundation has awarded a total of $1 million in grants to 40 organizations for projects designed to improve medication management and operating room safety. The grants range from $7,500 to $37,500 each, and are part of a healthcare quality-improvement program that Cardinal launched in 2008, according to a statement. Cardinal has […]